Escalating cancer prevalence and the increase in integration of radiation therapy as a key element in cancer treatment is expected to bolster the particle therapy market growth. Technology advancement and ongoing research endeavors have amplified the efficacy and safety of particle therapy, making it an appealing choice for both patients and healthcare providers.
Furthermore, the advantages of particle therapy, including less harm to healthy tissues and reduced long-term side effects propels its adoption. Government initiatives and financial backing to improve healthcare technologies, including the establishment of particle therapy facilities, also fuels market development.
Key industry players have established proton therapy centers worldwide. The surge in collaborations and partnerships between healthcare entities and research institutions aimed at broadening access to particle therapy services also contributes significantly to market expansion.
Particle therapy, a form of external beam radiation therapy, harnesses heavy particle beams in treatments such as proton and carbon ion therapy. Particularly effective for tumors situated near critical structures such as the brain or spine and confined to their original site, the therapy holds promise, especially for younger patients. It mitigates damage to healthy, developing tissue and minimizes long-term radiation therapy side effects.
Technological advancements in radiation therapy have enabled precise targeting, minimizing radiation exposure to healthy tissue. Particle therapy employs highly charged particles that deposit the majority of radiation directly into the tumor, sparing surrounding healthy tissue from significant exposure.
Proton therapy, the most rampant particle therapy modality, utilizes protons to generate radiation beams. According to the Particle Therapy Co-Operative Group (PTCOG) website, approximately 360,000 patients worldwide have undergone particle therapy treatments from 1975 to 2022.
| Attribute | Detail |
|---|---|
| Drivers |
|
The frequency of cancer surgical procedures has seen an uptick in recent years, leading to a corresponding rise in adoption of particle therapy to address post-surgical consequences. Particle beams possess unique physical properties that enable the preservation of normal tissue by minimizing the irradiated volume. This approach, grounded in radiobiological principles and supported by clinical data from photon therapy, holds promise for reducing the risk and severity of side effects, as well as secondary cancers.
Furthermore, particle therapy is gaining traction in clinical trials for the treatment of various cancers without surgical intervention or specific drug indications. The Medical Service Advisory Committee (MSAC) is currently evaluating the clinical indications for particle therapy, previously approved under the Australian Government's Medical Treatment Overseas Program (MTOP). Although the efficacy of particle therapy, utilizing either protons or ions, for individual tumor types is still under investigation, its introduction into clinical practice offers a novel avenue for enhancing cancer sensitivity to radiotherapy. Thus, the surge in usage in clinical trials is driving the particle therapy market value.
Cancer treatment encompasses various therapeutic approaches involving potent chemicals (chemotherapy) and powerful radiation (radiotherapy and proton therapy) aimed at eradicating cancerous cells within the body.
According to the GLOBOCAN 2020 estimates by the International Agency for Research on Cancer, there were approximately 19.3 million new cancer cases (excluding non-melanoma skin cancer) and nearly 10.0 million cancer-related deaths in 2020 worldwide.
The significant increase in incidence of cancer cases globally is expected to offer lucrative particle therapy market opportunities in the next few years. By 2040, it is anticipated that the global burden of cancer will surge to 27.5 million new cases and 16.3 million cancer-related deaths, largely propelled by the aging population.
Hospitals are central hubs for all treatment procedures, including particle therapy. The rise in number of cancer cases, which increases the admission of patients in hospitals, and macroeconomic success in providing particle therapy services using protons and electrons for treating cancers are likely to drive the hospital segment in terms of end-user in the particle therapy market during the forecast period.
All these factors are poised to be key drivers for particle therapy market growth throughout the forecast period.
The particle therapy market segmentation in terms of therapy includes proton therapy and heavy ion. Proton therapy has significant prominence within the particle therapy Industry. The increase in need for radiation therapy in cancer treatment, supported by favorable outcomes from clinical research emphasizes the efficacy of proton particle-beam therapies.
Furthermore, ongoing research endeavors are revealing the distinctive biological, immunomodulatory, and clinical impacts of protons, underscoring their unique properties relative to photons.
Based on services, the market is classified into cyclotrons, synchrotrons, and synchrocyclotrons. As per the particle therapy market analysis, cyclotrons have been integral to the landscape of radiotherapy since its early inception, and they are poised to play a significant role in future hospital-based facilities tailored for this purpose.
Modern cyclotron technology has evolved to fulfill all necessary requirements while remaining within reasonable budget constraints. Various cyclotron designs with specific performance capabilities are available to meet diverse needs. Cyclotrons have become a predominant choice for particle accelerators in particle therapy treatment due to their affordability and the abundance of technical expertise available. Majority of proton accelerators in operation currently are cyclotrons, as they can generate a continuous stream of protons, are more compact, and offer higher beam intensity compared to other alternatives.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest particle therapy market forecast, North America commands a significant share of the landscape, ascribed to the establishment of numerous laboratories in the U.S. and Canada. Statistics from surgery data indicate that 40% to 50% of patients receiving particle therapy treatment worldwide are treated in North America. The surge in usage of cyclotron technology to treat various types of cancers, and the growth in demand for advanced healthcare techniques and patient diagnosis, is anticipated to fuel market growth in this region during the forecast period.
In Europe, the number of clinical particle therapy centers has substantially increased. Currently, more than 4,000 adult patients receive particle therapy treatment annually across Europe.
In the APAC region, the rise in cancer cases, particularly among the geriatric population, technological advancements in healthcare products, and the surge in adoption of particle therapy products by hospitals and advanced cancer treatment centers, is poised to propel the market. Furthermore, the initiation of projects for particle therapy centers by key players, such as the Australian Bragg Centre for Proton Therapy and Research, is likely to contribute significantly to future market expansion in the APAC region.
The particle therapy market share is fragmented with the presence of a number of players. Advanced Oncotherapy plc, Danfysik A/S, Hitachi, Ltd., IBA Worldwide, Mevion Medical Systems, Inc., Optivus Proton Therapy, Inc., ProTom International, Inc., Provision Healthcare, and Varian Medical Systems, Inc., are the emerging players in the global market.
Key players have been profiled in the global particle therapy market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 603.5 Mn |
| Forecast Value in 2031 | More than US$ 1.3 Bn |
| CAGR | 8.6% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Mn/Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
It was valued at US$ 603.5 Mn in 2022
It is projected to reach more than US$ 1.3 Bn by the end of 2031
The CAGR is anticipated to be 8.6% from 2023 to 2031
North America is expected to account for largest share from 2023 to 2031
Advanced Oncotherapy plc, Danfysik A/S, Hitachi, Ltd., IBA Worldwide, Mevion Medical Systems, Inc., Optivus Proton Therapy, Inc., ProTom International, Inc., Provision Healthcare, and Varian Medical Systems, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Particle Therapy Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Particle Therapy Market Analysis and Forecast, 2017 - 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Reimbursement Scenario
5.3. Particle Therapy Facilities In Clinical Operations
5.4. Average Prices, by Region, 2022
5.5. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)
6. Global Particle Therapy Market Analysis and Forecast, By Therapy
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapy, 2017 - 2031
6.3.1. Proton Therapy
6.3.2. Heavy Ion Therapy (carbon therapy, He, pion)
6.4. Market Attractiveness Analysis, By Therapy
7. Global Particle Therapy Market Analysis and Forecast, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017 - 2031
7.3.1. Pediatric Cancer
7.3.2. Lung Cancer
7.3.3. Bladder Cancer
7.3.4. Brain & Spinal Cord Tumors (BSCT)
7.3.5. Breast Cancer
7.3.6. Gastrointestinal (GI) Cancers
7.3.7. Hepatocellular Carcinoma (HCC)
7.3.8. Head & Neck Cancers (HNC)
7.3.9. Others
7.4. Market Attractiveness Analysis, By Application
8. Global Particle Therapy Market Analysis and Forecast, By Services
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Services, 2017 - 2031
8.3.1. Cyclotrons
8.3.2. Synchrotrons
8.3.3. Synchrocyclotrons
8.4. Market Attractiveness Analysis, By Services
9. Global Particle Therapy Market Analysis and Forecast, By End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017 - 2031
9.3.1. Hospitals
9.3.2. Academic & Research Centers
9.4. Market Attractiveness Analysis, By End-user
10. Global Particle Therapy Market Analysis and Forecast, By Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Rest of the World
10.3. Market Attractiveness Analysis, By Region
11. North America Particle Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy, 2017 - 2031
11.2.1. Proton Therapy
11.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
11.3. Market Value Forecast, by Application, 2017 - 2031
11.3.1. Pediatric Cancer
11.3.2. Lung Cancer
11.3.3. Bladder Cancer
11.3.4. Brain & Spinal Cord Tumors (BSCT)
11.3.5. Breast Cancer
11.3.6. Gastrointestinal (GI) Cancers
11.3.7. Hepatocellular Carcinoma (HCC)
11.3.8. Head & Neck Cancers (HNC)
11.3.9. Others
11.4. Market Value Forecast, by Services, 2017 - 2031
11.4.1. Cyclotrons
11.4.2. Synchrotrons
11.4.3. Synchrocyclotrons
11.5. Market Value Forecast, by End-user, 2017 - 2031
11.5.1. Hospitals
11.5.2. Academic & Research Centers
11.6. Market Value Forecast, by Country, 2017 - 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Therapy
11.7.2. By Application
11.7.3. By Services
11.7.4. By End-user
11.7.5. By Country
12. Europe Particle Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy, 2017 - 2031
12.2.1. Proton Therapy
12.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
12.3. Market Value Forecast, by Application, 2017 - 2031
12.3.1. Pediatric Cancer
12.3.2. Lung Cancer
12.3.3. Bladder Cancer
12.3.4. Brain & Spinal Cord Tumors (BSCT)
12.3.5. Breast Cancer
12.3.6. Gastrointestinal (GI) Cancers
12.3.7. Hepatocellular Carcinoma (HCC)
12.3.8. Head & Neck Cancers (HNC)
12.3.9. Others
12.4. Market Value Forecast, by Services, 2017 - 2031
12.4.1. Cyclotrons
12.4.2. Synchrotrons
12.4.3. Synchrocyclotrons
12.5. Market Value Forecast, by End-user, 2017 - 2031
12.5.1. Hospitals
12.5.2. Academic & Research Centers
12.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Therapy
12.7.2. By Application
12.7.3. By Services
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Particle Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy, 2017 - 2031
13.2.1. Proton Therapy
13.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
13.3. Market Value Forecast, by Application, 2017 - 2031
13.3.1. Pediatric Cancer
13.3.2. Lung Cancer
13.3.3. Bladder Cancer
13.3.4. Brain & Spinal Cord Tumors (BSCT)
13.3.5. Breast Cancer
13.3.6. Gastrointestinal (GI) Cancers
13.3.7. Hepatocellular Carcinoma (HCC)
13.3.8. Head & Neck Cancers (HNC)
13.3.9. Others
13.4. Market Value Forecast, by Services, 2017 - 2031
13.4.1. Cyclotrons
13.4.2. Synchrotrons
13.4.3. Synchrocyclotrons
13.5. Market Value Forecast, by End-user, 2017 - 2031
13.5.1. Hospitals
13.5.2. Academic & Research Centers
13.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Therapy
13.7.2. By Application
13.7.3. By Services
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Rest of the World Particle Therapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapy, 2017 - 2031
14.2.1. Proton Therapy
14.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
14.3. Market Value Forecast, by Application, 2017 - 2031
14.3.1. Pediatric Cancer
14.3.2. Lung Cancer
14.3.3. Bladder Cancer
14.3.4. Brain & Spinal Cord Tumors (BSCT)
14.3.5. Breast Cancer
14.3.6. Gastrointestinal (GI) Cancers
14.3.7. Hepatocellular Carcinoma (HCC)
14.3.8. Head & Neck Cancers (HNC)
14.3.9. Others
14.4. Market Value Forecast, by Services, 2017 - 2031
14.4.1. Cyclotrons
14.4.2. Synchrotrons
14.4.3. Synchrocyclotrons
14.5. Market Value Forecast, by End-user, 2017 - 2031
14.5.1. Hospitals
14.5.2. Academic & Research Centers
14.6. Market Attractiveness Analysis
14.6.1. By Therapy
14.6.2. By Application
14.6.3. By Services
14.6.4. By End-user
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2022
15.3. Company Profiles
15.3.1. Advanced Oncotherapy plc
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. Danfysik A/S
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. Hitachi, Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. IBA Worldwide
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. Mevion Medical Systems, Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Optivus Proton Therapy, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. Protom International, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Provision Healthcare
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Varian Medical Systems, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
List of Tables
Table 01: Global Particle Therapy Market Value (US$ Mn) Forecast, by Therapy 2017 - 2031
Table 02: Global Particle Therapy Market Value (US$ Mn) Forecast, by Application, 2017 - 2031
Table 03: Global Particle Therapy Market Value (US$ Mn) Forecast, by Service, 2017 - 2031
Table 04: Global Particle Therapy Market Value (US$ Mn) Forecast, by End-user, 2017 - 2031
Table 05: Global Particle Therapy Market Value (US$ Mn) Forecast, by Region, 2017 - 2031
Table 06: North America Particle Therapy Market Value (US$ Mn) Forecast, by Country, 2017 - 2031
Table 07: North America Particle Therapy Market Value (US$ Mn) Forecast, by Therapy, 2017 - 2031
Table 08: North America Particle Therapy Market (US$ Mn) Forecast, by Application, 2017 - 2031
Table 09: North America Particle Therapy Market Value (US$ Mn) Forecast, by Service, 2017 - 2031
Table 10: North America Particle Therapy Market Value (US$ Mn) Forecast, by End-user, 2017 - 2031
Table 11: Europe Particle Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017 - 2031
Table 12: Europe Particle Therapy Market Value (US$ Mn) Forecast, by Therapy, 2017 - 2031
Table 13: Europe Particle Therapy Market (US$ Mn) Forecast, by Application, 2017 - 2031
Table 14: Europe Particle Therapy Market Value (US$ Mn) Forecast, by Service, 2017 - 2031
Table 15: Europe Particle Therapy Market Value (US$ Mn) Forecast, by End-user, 2017 - 2031
Table 16: Asia Pacific Particle Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017 - 2031
Table 17: Asia Pacific Particle Therapy Market Value (US$ Mn) Forecast, by Therapy, 2017 - 2031
Table 18: Asia Pacific Particle Therapy Market (US$ Mn) Forecast, by Application, 2017 - 2031
Table 19: Asia Pacific Particle Therapy Market Value (US$ Mn) Forecast, by Service, 2017 - 2031
Table 20: Asia Pacific Particle Therapy Market Value (US$ Mn) Forecast, by End-user, 2017 - 2031
Table 21: Rest of the World Particle Therapy Market Value (US$ Mn) Forecast, by Therapy, 2017 - 2031
Table 22: Rest of the World Particle Therapy Market (US$ Mn) Forecast, by Application, 2017 - 2031
Table 23: Rest of the World Particle Therapy Market Value (US$ Mn) Forecast, by Service, 2017 - 2031
Table 24: Rest of the World Particle Therapy Market Value (US$ Mn) Forecast, by End-user, 2017 - 2031
List of Figures
Figure 01: Global Particle Therapy Market Value (US$ Mn) Forecast, 2017 - 2031
Figure 02: Global Particle Therapy Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 03: Global Particle Therapy Market Attractiveness Analysis, by Therapy, 2023 - 2031
Figure 04: Global Particle Therapy Market Value (US$ Mn) Forecast, by Proton Therapy, 2017 - 2031
Figure 05: Global Particle Therapy Market Value (US$ Mn) Forecast, by Heavy Ion Therapy, 2017 - 2031
Figure 06: Global Particle Therapy Market Value Share Analysis, by Application, 2022 and 2031
Figure 07: Global Particle Therapy Market Attractiveness Analysis, by Application, 2023 - 2031
Figure 08: Global Particle Therapy Market Value (US$ Mn) Forecast, by Pediatric Cancer, 2017 - 2031
Figure 09: Global Particle Therapy Market Value (US$ Mn) Forecast, by Lung Cancer, 2017 - 2031
Figure 10: Global Particle Therapy Market Value (US$ Mn) Forecast, by Bladder Cancer, 2017 - 2031
Figure 11: Global Particle Therapy Market Value (US$ Mn) Forecast, by Brain &Spinal Cord Tumors, 2017 - 2031
Figure 12: Global Particle Therapy Market Value (US$ Mn) Forecast, by Breast Cancer, 2017 - 2031
Figure 13: Global Particle Therapy Market Value (US$ Mn) Forecast, by Gastrointestinal (GI) Cancers, 2017 - 2031
Figure 14: Global Particle Therapy Market Value (US$ Mn) Forecast, by Hepatocellular Carcinoma (HCC), 2017 - 2031
Figure 15: Global Particle Therapy Market Value (US$ Mn) Forecast, by Head & Neck Cancers (HNC), 2017 - 2031
Figure 16: Global Particle Therapy Market Value (US$ Mn) Forecast, by Other Cancers, 2017 - 2031
Figure 17: Global Particle Therapy Market, by Service, 2022 and 2031
Figure 18: Global Particle Therapy Market Attractiveness Analysis, by Service, 2023 - 2031
Figure 19: Global Particle Therapy Market Value (US$ Mn) Forecast, by Cyclotrons, 2017 - 2031
Figure 20: Global Particle Therapy Market Value (US$ Mn) Forecast, by Synchrotrons, 2017 - 2031
Figure 21: Global Particle Therapy Market Value (US$ Mn) Forecast, by Synchrocyclotrons, 2017 - 2031
Figure 22: Global Particle Therapy Market Value Share Analysis, by End-user, 2022 and 2031
Figure 23: Global Particle Therapy Market Attractiveness Analysis, by End-user, 2023 - 2031
Figure 24: Global Particle Therapy Market (US$ Mn), by Hospitals, 2017 - 2031
Figure 25: Global Particle Therapy Market (US$ Mn), by Academic & Research Institutes, 2017 - 2031
Figure 26: Global Particle Therapy Market Value Share Analysis, by Region, 2022 and 2031
Figure 27: Global Particle Therapy Market Attractiveness Analysis, by Region, 2023 - 2031
Figure 28: North America Particle Therapy Market Value (US$ Mn) Forecast, 2017 - 2031
Figure 29: North America Particle Therapy Market Value Share Analysis, by Country, 2022 and 2031
Figure 30: North America Particle Therapy Market Attractiveness Analysis, by Country, 2023 - 2031
Figure 31: North America Particle Therapy Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 32: North America Particle Therapy Market Attractiveness Analysis, by Therapy, 2023 - 2031
Figure 33: North America Particle Therapy Market Value Share Analysis, by Application, 2022 and 2031
Figure 34: North America Particle Therapy Market Attractiveness Analysis, by Application, 2023 - 2031
Figure 35: North America Particle Therapy Market Value Share Analysis, by Service, 2022 and 2031
Figure 36: North America Particle Therapy Market Attractiveness Analysis, by Service, 2023 - 2031
Figure 37: North America Particle Therapy Market Value Share Analysis, by End-user, 2022 and 2031
Figure 38: North America Particle Therapy Market Attractiveness Analysis, by End-user, 2023 - 2031
Figure 39: Europe Particle Therapy Market Value (US$ Mn) Forecast, 2017 - 2031
Figure 40: Europe Particle Therapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 41: Europe Particle Therapy Market Attractiveness Analysis, by Country/Sub-region, 2023 - 2031
Figure 42: Europe Particle Therapy Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 43: Europe Particle Therapy Market Attractiveness Analysis, by Therapy, 2023 - 2031
Figure 44: Europe Particle Therapy Market Value Share Analysis, by Application, 2022 and 2031
Figure 45: Europe Particle Therapy Market Attractiveness Analysis, by Application, 2023 - 2031
Figure 46: Europe Particle Therapy Market Value Share Analysis, by Service, 2022 and 2031
Figure 47: Europe Particle Therapy Market Attractiveness Analysis, by Service, 2023 - 2031
Figure 48: Europe Particle Therapy Market Value Share Analysis, by End-user, 2022 and 2031
Figure 49: Europe Particle Therapy Market Attractiveness Analysis, by End-user, 2023 - 2031
Figure 50: Asia Pacific Particle Therapy Market Value (US$ Mn) Forecast, 2017 - 2031
Figure 51: Asia Pacific Particle Therapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 52: Asia Pacific Particle Therapy Market Attractiveness Analysis, by Country/Sub-region, 2023 - 2031
Figure 53: Asia Pacific Particle Therapy Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 54: Asia Pacific Particle Therapy Market Attractiveness Analysis, by Therapy, 2023 - 2031
Figure 55: Asia Pacific Particle Therapy Market Value Share Analysis, by Application, 2022 and 2031
Figure 56: Asia Pacific Particle Therapy Market Attractiveness Analysis, by Application, 2023 - 2031
Figure 57: Asia Pacific Particle Therapy Market Value Share Analysis, by Service, 2022 and 2031
Figure 58: Asia Pacific Particle Therapy Market Attractiveness Analysis, by Service, 2023 - 2031
Figure 59: Asia Pacific Particle Therapy Market Value Share Analysis, by End-user, 2022 and 2031
Figure 60: Asia Pacific Particle Therapy Market Attractiveness Analysis, by End-user, 2023 - 2031
Figure 61: Rest of the World Particle Therapy Market Value (US$ Mn) Forecast, 2017 - 2031
Figure 62: Rest of the World Particle Therapy Market Value Share Analysis, by Therapy, 2022 and 2031
Figure 63: Rest of the World Particle Therapy Market Attractiveness Analysis, by Therapy, 2023 - 2031
Figure 64: Rest of the World Particle Therapy Market Value Share Analysis, by Application, 2022 and 2031
Figure 65: Rest of the World Particle Therapy Market Attractiveness Analysis, by Application, 2023 - 2031
Figure 66: Rest of the World Particle Therapy Market Value Share Analysis, by Service, 2022 and 2031
Figure 67: Rest of the World Particle Therapy Market Attractiveness Analysis, by Service, 2023 - 2031
Figure 68: Rest of the World Particle Therapy Market Value Share Analysis, by End-user, 2022 and 2031
Figure 69: Rest of the World Particle Therapy Market Attractiveness Analysis, by End-user, 2023 - 2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Particle Therapy Market
